Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized cyclin-dependent kinase 8 (CDK8) and/or CDK19 inhibitors reported to be useful for the treatment of cancer.
Daegu-Gyeongbuk Medical Innovation Foundation has disclosed estrogen receptor α (ER-α; ESR1) antagonists reported to be useful for the treatment of cancer.
Trio Medicines Ltd. has described β2-adrenoceptor (ADRB2) antagonists reported to be useful for the treatment of cancer, cerebral cavernous malformations, chronic heart failure, chronic obstructive pulmonary disease, hereditary hemorrhagic telangiectasia, migraine and asthma.
Addex Pharma SA has divulged metabotropic glutamate mGlu7 receptor negative allosteric modulators reported to be useful for the treatment of pain, ear disorders and neurological disorders.
Genescience Pharmaceuticals Co. Ltd. has identified melanocortin MC4 receptor antagonists reported to be useful for the treatment of cachexia, anorexia nervosa, nausea and vomiting, sarcopenia, neuropathic pain, post-traumatic stress disorder and muscle and bone disorders.
Researchers at Rheinisch-Westfaelische Technische Hochschule Aachen University and University of Arizona have synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a DYRK1A and/or DYRK1B and/or DYRK2 and/or DYRK3 and/or CLK1 and/or CLK2 and/or CLK3 and/or CLK4 and/or HASPIN targeting moiety through a linker reported to be useful for the treatment of cancer, viral infection, diabetes, inflammatory disorders, Alzheimer’s, Parkinson’s, Huntington’s and autoimmune diseases, among others.
Even patent attorneys aren’t particularly collectively excited about standard essential patents, but that hasn’t stopped the U.S. Patent and Trademark Office from signing a memorandum of understanding with the U.K. Intellectual Property Office to collaborate on policies related to these patents.
The first patenting from San Francisco-based Ananya Health Inc. describes its development of a closed-loop cryoablation platform to freeze abnormal cells before they become cervical cancer. The company’s device achieves ablative temperatures without consumable gas, making the procedure portable, battery-powered, and ten times cheaper than traditional cryoablation.
RSS
